Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC

June 12th 2025

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

MVdeltaC Receives FDA Orphan Drug Designation in Pleural Mesothelioma

June 12th 2025

The oncolytic virus candidate MVdeltaC has received FDA orphan drug designation for the treatment of patients with pleural mesothelioma.

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs

June 12th 2025

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Dr Kalinsky on the Importance of Biomarker Testing in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, discusses the importance of biomarker testing in guiding therapeutic decision-making in HR-positive, HER2-negative breast cancer.

T-DXd Plus Pertuzumab Displays Significant PFS Benefit Over SOC Therapy in Frontline HER2+ Advanced Breast Cancer

June 10th 2025

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Dr Wermke on the Efficacy and Safety of Obrixtamig With Topotecan in Advanced SCLC

June 9th 2025

Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.

UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC

June 9th 2025

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

Real-World Data Help Fill the Gaps Left by Clinical Trial Results in Urothelial Carcinoma

June 9th 2025

David J. Benjamin, MD, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target

June 9th 2025

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL

June 6th 2025

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

FDA Receives NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

June 6th 2025

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Accelerated FDA Approval Establishes Role of Avutometinib/Defactinib in KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer

June 4th 2025

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma

June 4th 2025

Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

June 3rd 2025

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma

June 3rd 2025

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.

Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC

June 3rd 2025

Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.

Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

June 3rd 2025

Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

June 2nd 2025

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.